Lancet Infectious Diseases
-
{
- All
- News
- Videos
-
Addressing Undernutrition Could Prevent 2.3 Million Tuberculosis Cases Worldwide: Lancet Study
Addressing undernutrition could prevent up to 2.3 million tuberculosis cases worldwide, representing 23.7 per cent of infections among adults in 2023, according to a modelling study published in The Lancet Global Health journal.
-
Antibiotic Resistance Is Responsible For 87% Of India's Typhoid Economic Burden: Lancet Study
Antibiotic-resistant typhoid infections accounted for at least 87 per cent of India's disease-related economic burden in 2023, according to a study in The Lancet Regional Health Southeast Asia.
-
Chronic Lifestyle Diseases Now Kill More Indians Than Infections, New Lancet Study Shows
A sweeping new Global Burden of Disease (GBD) analysis published in The Lancet reveals that by 2023, non-communicable diseases (NCDs) have overtaken infectious diseases as the leading cause of death in India.
-
Three In Every Four Animal Bites In India Are Due To Dogs: Lancet Study
Three in every four animal bites are due to dogs, with over 5,700 deaths in humans estimated to occur each year due to rabies in India, according to a study published in The Lancet Infectious Diseases journal.
-
New Drug 95% Effective Against Sleeping Sickness In Adults: Lancet Study
A new, single-dose oral treatment for sleeping sickness is 95 per cent effective in adults and adolescents, regardless of disease stage, according to a study published in The Lancet Infectious Diseases.
-
Lancet Study Says Heat-Related Deaths Among Elderly Have Gone Up By 68%
The Lancet report said that changing climate is exacerbating the risk of infectious disease outbreaks and threatening global food security.
-
Over 42 Lakh Deaths Prevented In India By Covid Vaccines In 2021: Report
COVID-19 vaccines prevented over 42 lakh potential deaths in India in 2021, said a study published in The Lancet Infectious Diseases journal, which based its findings on estimates of "excess" mortalities in the country during the pandemic.
-
"Covaxin Safe For Kids Aged 2-18": Here's What Bharat Biotech Says On Side-Effects
Data on Covaxin for children has been published online in The Lancet Infectious Diseases journal on June 16
-
Covishield Remained Effective Even During Delta Surge: Lancet Study
Covishield vaccine remained effective against moderate-to-severe COVID-19 even during the deadly surge dominated by the highly transmissible delta variant of SARS-CoV-2, according to a study published in The Lancet Infectious Diseases journal.
-
Covaxin 50% Effective When Delta Was Dominant, Shows Lancet Study
Two doses of Covaxin are 50 per cent effective against symptomatic disease, according to the first real-world assessment of India's indigenous COVID-19 vaccine published in The Lancet Infectious Diseases journal.
-
Chinese Covid Vaccine Safe, Effective In Children, Adolescents: Lancet Study
Two doses of the China-made COVID-19 vaccine, CoronaVac, are safe and produce a strong antibody response among children and adolescents aged 3-17 years, according to a study published in The Lancet Infectious Diseases journal.
-
Covaxin Phase 1 Trial Clears Lancet Review, Phase 3 Trial Ongoing
Covaxin, India's first indigenous vaccine against COVID-19, showed enhanced immune response without any serious side effects in the Phase 1 trials, according to the results published in well-respected Lancet Infectious Disease journal on Friday.
-
Health Troubles Persist For Ebola Survivors: Study
The lucky ones who survive Ebola may suffer potentially blinding vision problems, hearing loss and joint pain for months afterwards, medical experts reported on Wednesday.
-
'Invincible' Bacteria Threatens Global Epidemic: Study
Medicine's final line of defence against deadly disease has been breached, raising the spectre of a global epidemic, scientists say, after finding bacteria resistant to last-resort antibiotics.
-
Addressing Undernutrition Could Prevent 2.3 Million Tuberculosis Cases Worldwide: Lancet Study
Addressing undernutrition could prevent up to 2.3 million tuberculosis cases worldwide, representing 23.7 per cent of infections among adults in 2023, according to a modelling study published in The Lancet Global Health journal.
-
Antibiotic Resistance Is Responsible For 87% Of India's Typhoid Economic Burden: Lancet Study
Antibiotic-resistant typhoid infections accounted for at least 87 per cent of India's disease-related economic burden in 2023, according to a study in The Lancet Regional Health Southeast Asia.
-
Chronic Lifestyle Diseases Now Kill More Indians Than Infections, New Lancet Study Shows
A sweeping new Global Burden of Disease (GBD) analysis published in The Lancet reveals that by 2023, non-communicable diseases (NCDs) have overtaken infectious diseases as the leading cause of death in India.
-
Three In Every Four Animal Bites In India Are Due To Dogs: Lancet Study
Three in every four animal bites are due to dogs, with over 5,700 deaths in humans estimated to occur each year due to rabies in India, according to a study published in The Lancet Infectious Diseases journal.
-
New Drug 95% Effective Against Sleeping Sickness In Adults: Lancet Study
A new, single-dose oral treatment for sleeping sickness is 95 per cent effective in adults and adolescents, regardless of disease stage, according to a study published in The Lancet Infectious Diseases.
-
Lancet Study Says Heat-Related Deaths Among Elderly Have Gone Up By 68%
The Lancet report said that changing climate is exacerbating the risk of infectious disease outbreaks and threatening global food security.
-
Over 42 Lakh Deaths Prevented In India By Covid Vaccines In 2021: Report
COVID-19 vaccines prevented over 42 lakh potential deaths in India in 2021, said a study published in The Lancet Infectious Diseases journal, which based its findings on estimates of "excess" mortalities in the country during the pandemic.
-
"Covaxin Safe For Kids Aged 2-18": Here's What Bharat Biotech Says On Side-Effects
Data on Covaxin for children has been published online in The Lancet Infectious Diseases journal on June 16
-
Covishield Remained Effective Even During Delta Surge: Lancet Study
Covishield vaccine remained effective against moderate-to-severe COVID-19 even during the deadly surge dominated by the highly transmissible delta variant of SARS-CoV-2, according to a study published in The Lancet Infectious Diseases journal.
-
Covaxin 50% Effective When Delta Was Dominant, Shows Lancet Study
Two doses of Covaxin are 50 per cent effective against symptomatic disease, according to the first real-world assessment of India's indigenous COVID-19 vaccine published in The Lancet Infectious Diseases journal.
-
Chinese Covid Vaccine Safe, Effective In Children, Adolescents: Lancet Study
Two doses of the China-made COVID-19 vaccine, CoronaVac, are safe and produce a strong antibody response among children and adolescents aged 3-17 years, according to a study published in The Lancet Infectious Diseases journal.
-
Covaxin Phase 1 Trial Clears Lancet Review, Phase 3 Trial Ongoing
Covaxin, India's first indigenous vaccine against COVID-19, showed enhanced immune response without any serious side effects in the Phase 1 trials, according to the results published in well-respected Lancet Infectious Disease journal on Friday.
-
Health Troubles Persist For Ebola Survivors: Study
The lucky ones who survive Ebola may suffer potentially blinding vision problems, hearing loss and joint pain for months afterwards, medical experts reported on Wednesday.
-
'Invincible' Bacteria Threatens Global Epidemic: Study
Medicine's final line of defence against deadly disease has been breached, raising the spectre of a global epidemic, scientists say, after finding bacteria resistant to last-resort antibiotics.
